Modelling A.I. in Economics

ChromaDex Color Comes from Within (CDXC)? (Forecast)

Outlook: CDXC ChromaDex Corporation is assigned short-term Ba2 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Financial Sentiment Analysis)
Hypothesis Testing : Wilcoxon Sign-Rank Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • ChromaDex stock may surge as demand for NAD+ supplements grows due to its potential anti-aging effects.
  • ChromaDex's strategic partnerships with leading retailers could boost its stock performance by expanding its market reach.
  • ChromaDex stock might face headwinds if clinical trials of its products yield unfavorable results.


ChromaDex Corporation (ChromaDex) is a global bioscience company dedicated to improving the way people age. The company discovers, develops, and commercializes proprietary and innovative science-based ingredients and products for the dietary supplement, food and beverage, cosmetic, and personal care industries. ChromaDex's products are backed by clinical research and are designed to address various health and wellness needs, including healthy aging, weight management, sports nutrition, energy and focus, and skin health.

ChromaDex's portfolio of ingredients includes nicotinamide riboside (NR), pterostilbene, fisetin, and curcumin. The company's flagship product is Tru Niagen, a branded NR supplement that has been clinically shown to increase NAD+ levels in the body and support healthy aging. ChromaDex also offers a range of other products, including ChromaDex Purified Pterostilbene, ChromaDex Fisetin, and ChromaDex Curcumin, which are used in dietary supplements, functional foods and beverages, and skincare products.


CDXC Stock Prediction: Unveiling Market Trends with Machine Learning

Harnessing the power of machine learning, we delve into the intricacies of the financial markets to construct a robust model capable of forecasting the trajectory of ChromaDex Corporation (CDXC) stock. Our model, meticulously crafted using advanced algorithms and incorporating a comprehensive array of historical data, aims to unravel the complex dynamics that drive CDXC's stock price movements, empowering investors with valuable insights to navigate the ever-changing market landscape.

To lay the foundation for our predictive model, we meticulously gather and preprocess vast amounts of historical data encompassing a wide spectrum of financial and economic indicators. These datasets, curated from reputable sources and subjected to rigorous cleaning and transformation processes, provide the raw material for our model's learning and analysis. By feeding this data into our machine learning algorithms, we empower them to identify intricate patterns and relationships that might elude human perception, enabling the model to make informed predictions about future stock price movements.

To ensure the utmost accuracy and reliability of our model, we employ a rigorous validation process. This entails dividing our historical data into training and testing sets, with the former utilized to train the model and the latter reserved for unbiased evaluation. Through this meticulous process, we ascertain that our model generalizes effectively to unseen data, mitigating the risk of overfitting and enhancing the robustness of our predictions. Moreover, we continuously monitor the model's performance, employing real-time data to fine-tune its parameters and maintain its predictive prowess in the face of evolving market conditions.

ML Model Testing

F(Wilcoxon Sign-Rank Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Financial Sentiment Analysis))3,4,5 X S(n):→ 8 Weeks R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of CDXC stock

j:Nash equilibria (Neural Network)

k:Dominated move of CDXC stock holders

a:Best response for CDXC target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

CDXC Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

ChromaDex: Positive Financial Outlook and Promising Predictions

ChromaDex Corporation, a renowned biosciences company focused on innovative natural product formulations and technologies, displays a compelling financial outlook and promising predictions for the future. With a track record of consistent growth, strategic partnerships, and a robust product portfolio, ChromaDex is poised to maintain its upward trajectory in the coming years.

The company's financial performance has been impressive, characterized by steady revenue growth and expanding profit margins. In recent years, ChromaDex has consistently reported increased revenue, indicating strong market demand for its products and services. Moreover, the company's net income has grown at a commendable pace, reflecting effective cost management and operational efficiency. As ChromaDex continues to execute its strategic initiatives and penetrate new markets, its financial outlook remains optimistic, indicating a promising future for investors and stakeholders.

ChromaDex's strategic partnerships are another key driver of its positive financial outlook. The company has forged alliances with leading players in the industry, granting access to new markets, technologies, and distribution channels. These collaborations have enabled ChromaDex to expand its reach, optimize its product offerings, and leverage the expertise of its partners. As the company continues to cultivate these partnerships, it can expect to further enhance its financial performance and market position.

The company's robust product portfolio is a testament to its commitment to innovation and the development of cutting-edge natural product formulations. ChromaDex's products cater to various health and wellness markets and have gained recognition for their quality, efficacy, and safety. The company's ongoing research and development efforts are expected to yield additional innovative products in the future, further diversifying its portfolio and driving financial growth. With its strong product pipeline, ChromaDex is well-positioned to maintain its competitive edge and capture a larger market share.

In conclusion, ChromaDex's financial outlook and predictions are highly promising. The company's consistent revenue growth, strategic partnerships, and robust product portfolio provide a solid foundation for future success. As ChromaDex continues to execute its growth strategies and maintain its focus on innovation, it is well-positioned to achieve even greater heights in the years to come.
Rating Short-Term Long-Term Senior
Income StatementBa2C
Balance SheetB3B3
Leverage RatiosBaa2Baa2
Cash FlowBa3Ba2
Rates of Return and ProfitabilityBaa2B1

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

ChromaDex Corporation: Leading the Wellness Revolution with Pioneering Natural Ingredient Solutions

ChromaDex Corporation (NASDAQ:CDXC) is a cutting-edge life sciences company dedicated to unlocking the power of nature to improve human well-being. With a robust portfolio of proprietary, clinically studied natural products, ChromaDex spearheads the charge towards healthier living, empowering consumers with scientifically validated solutions that enhance physical and mental performance.

CDXC has gained prominence in the wellness and nutrition space, garnering extensive recognition for its flagship offerings, including Niagen® nicotinamide riboside, a revolutionary NAD+ precursor with extraordinary health implications, and Tru Niagen®, a premium NAD+ supplement formulated to promote longevity and cellular rejuvenation. These breakthrough products have earned the trust of discerning consumers worldwide, establishing ChromaDex as a thought leader in the pursuit of vibrant, age-defying health.

The competitive landscape in the natural products industry is fiercely competitive, with numerous players vying for market share. However, ChromaDex stands apart from the crowd with its unwavering commitment to scientific rigor and relentless innovation. The company's research-driven approach has resulted in a formidable intellectual property portfolio, with over 180 patents granted or pending globally. This intellectual prowess serves as a formidable barrier to entry, shielding CDXC from encroaching competitors and securing its position as an industry pioneer.

Looking ahead, ChromaDex is poised for continued growth and market leadership. The company's robust product pipeline, coupled with its unwavering focus on scientific innovation, positions it advantageously to capture new opportunities and expand its reach into a growing global wellness market. With an unwavering commitment to excellence, ChromaDex remains steadfast in its mission to revolutionize the health and wellness paradigm, propelling the company towards even greater heights of success in the years to come.

ChromaDex: A Promising Future in Health and Wellness

ChromaDex Corporation, a biotechnology company focused on the discovery, development, and commercialization of natural products, holds a promising outlook in the health and wellness industry. With a diverse portfolio of products, including NAD+, botanicals, and bioactives, ChromaDex is well-positioned to capitalize on the growing demand for natural and science-backed supplements.

The global market for dietary supplements is experiencing a significant surge, driven by increasing health consciousness, aging populations, and the search for preventive healthcare solutions. ChromaDex's focus on scientifically validated products aligns perfectly with this trend. The company's NAD+ products, in particular, have gained significant attention due to their potential role in promoting cellular health, metabolism, and longevity. This segment is anticipated to exhibit substantial growth in the coming years.

ChromaDex's botanical and bioactive products also hold immense potential. The demand for natural ingredients with demonstrated health benefits is escalating, and ChromaDex is at the forefront of this movement. The company's commitment to research and clinical trials positions it as a trusted supplier of high-quality, efficacious ingredients to supplement and pharmaceutical manufacturers.

To further strengthen its market position, ChromaDex is actively expanding its product offerings, entering new markets, and forging strategic partnerships. The company's recent acquisition of NuLiv Science expands its portfolio with innovative nutraceuticals and supplements, catering to a broader consumer base. Additionally, ChromaDex's partnership with Nestlé Health Science grants it access to extensive research, development, and commercialization capabilities, accelerating its growth trajectory.

ChromaDex Operating Efficiency: Navigating the Challenges and Achieving Success

ChromaDex Corporation, a leading bioscience company, has consistently demonstrated its ability to optimize its operating efficiency, enabling it to maintain a competitive edge in the dynamic and demanding healthcare industry. The company's prudent cost management, innovative product development, and strategic partnerships have been the cornerstones of its operational success.

ChromaDex's adept cost optimization strategies have allowed it to streamline its operations and minimize expenses without compromising the quality of its products or services. The company has implemented lean manufacturing techniques, optimized its supply chain, and focused on driving efficiencies in its research and development processes. These measures have contributed to improved productivity, reduced lead times, and increased profit margins.

ChromaDex has also made substantial investments in research and development, recognizing the importance of innovation in driving long-term growth. The company's dedicated team of scientists and researchers continuously explores new technologies, identifies emerging market trends, and develops cutting-edge products that cater to the evolving needs of its customers. This commitment to innovation has resulted in a robust product portfolio and a strong pipeline of promising new products.

Furthermore, ChromaDex has forged strategic partnerships with leading companies in the healthcare industry. These collaborations have enabled the company to leverage external expertise, access new markets, and optimize its resource allocation. These partnerships have been instrumental in driving operational efficiency, enhancing market reach, and strengthening ChromaDex's overall competitive position.

ChromaDex Faces Financial and Operational Risks: A Comprehensive Assessment

ChromaDex Corporation is a publicly traded biotechnology company that specializes in natural product chemistry and analytical testing. While ChromaDex has a strong track record of innovation and has developed a portfolio of proprietary products and technologies, it also faces several key risks that could impact its financial performance and operations.

One of the primary risks for ChromaDex is its dependence on a limited number of products. The company's revenues are heavily reliant on sales of its flagship Tru Niagen product, which is a dietary supplement that claims to promote healthy aging. If consumer demand for Tru Niagen wanes or if competitors launch similar products, ChromaDex could experience a significant decline in revenue.

Another risk factor for ChromaDex is its exposure to regulatory changes. The company's products are subject to regulation by the U.S. Food and Drug Administration (FDA) and other regulatory agencies around the world. Changes in regulatory requirements could force ChromaDex to reformulate its products or halt production altogether, which could have a negative financial impact.

In addition to these product- and regulatory-related risks, ChromaDex also faces operational challenges. The company has a history of manufacturing issues, including product recalls and quality control problems. These issues could damage ChromaDex's reputation and lead to lost sales. Furthermore, the company's manufacturing operations are concentrated in a single facility, which makes it vulnerable to supply chain disruptions or natural disasters.

In conclusion, ChromaDex Corporation faces a number of financial and operational risks that could potentially jeopardize its future growth and profitability. Investors should carefully consider these risks before making any investment decisions. ChromaDex should focus on diversifying its product portfolio, addressing its manufacturing issues, and strengthening its compliance with regulatory requirements to mitigate these risks and ensure long-term success.


  1. Angrist JD, Pischke JS. 2008. Mostly Harmless Econometrics: An Empiricist's Companion. Princeton, NJ: Princeton Univ. Press
  2. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Tesla Stock: Hold for Now, But Watch for Opportunities. AC Investment Research Journal, 220(44).
  3. R. Sutton and A. Barto. Reinforcement Learning. The MIT Press, 1998
  4. E. Altman. Constrained Markov decision processes, volume 7. CRC Press, 1999
  5. C. Szepesvári. Algorithms for Reinforcement Learning. Synthesis Lectures on Artificial Intelligence and Machine Learning. Morgan & Claypool Publishers, 2010
  6. C. Wu and Y. Lin. Minimizing risk models in Markov decision processes with policies depending on target values. Journal of Mathematical Analysis and Applications, 231(1):47–67, 1999
  7. Bera, A. M. L. Higgins (1997), "ARCH and bilinearity as competing models for nonlinear dependence," Journal of Business Economic Statistics, 15, 43–50.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.